APLM APOLLOMICS INC.

Apollomics Announces Presentation at the 2024 BIO International Convention

Apollomics Announces Presentation at the 2024 BIO International Convention

FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

BIO International Convention (June 3-6, 2024)

Format: In-person

Location: San Diego, California

Presentation Date: Tuesday, June 4, 2024

Location: Theater 2 located in Hall A of the Exhibition Hall at the San Diego Convention Center

Presentation Time: 3:15 p.m.

Presenter: Sanjeev Redkar, PhD, President and Executive Director of Apollomics

Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact .

About

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit .

CONTACTS 

Investor Relations 

Peter Vozzo 

ICR Westwicke 

 

 

Media Relations 

Sean Leous 

ICR Westwicke 

 

 



EN
29/05/2024

Underlying

APLMAPOLLOMICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOLLOMICS INC.

 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Reports First Half 2025 Financial Results

Apollomics Reports First Half 2025 Financial Results FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 202...

December 22, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Settlement of Cayman Litigation FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims b...

November 19, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Changes to its Board of Directors and Composition...

Apollomics Announces Changes to its Board of Directors and Composition of Committees FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16...

November 18, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Foll...

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation Nasdaq Hearing Cancellation and Continued Listing FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (...

October 15, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics, Inc. Company Operational Continuity Update

Apollomics, Inc. Company Operational Continuity Update FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer,...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch